Increasing T Cell Versatility with SUPRA CARs.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 29856949.
- Also identified by DOI 10.1016/j.cell.2018.05.030.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Chimeric antigen receptor (CAR) T cells offer a promising treatment option for advanced cancers resistant to standard therapy. Here, Cho et al. report a split-CAR design that enables the engineering of multi-feature CAR-T cells, aiming to address current challenges limiting the safety and efficacy of CAR-T cells for cancer treatment.
Medical subject headings
- Neoplasms
- T-Lymphocytes